← All stocks

BlossomHill Therapeutics, Inc.

BLSM Net buying
CIK 0001839970 #3158 in the set updated 17 Sep 2026
Bought (12 mo)
$25.18M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$25.18M
+$25.18M against sales at will

By person

9 insiders · 7 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
GORDON CARL L
Director
$10.00M (1)
+$10.00M
2,714,279
$43.43M
ORBIMED ADVISORS LLC entity
Director
$10.00M (1)
+$10.00M
2,714,279
$43.43M
Chen Bihua
Director
$5.00M (1)
+$5.00M
3,614,034
$57.82M
Schmid John P.
Director
$96.00K (1)
+$96.00K
6,000
$96.00K
Liptak Vincent Paul
General Counsel
$74.70K (2)
+$74.70K
134,099
$2.15M
+25.7%
Keyes Jason A
Chief Financial Officer
$11.20K (1)
+$11.20K
700
$11.20K
Agrawal Sundeep
Director
578,524
$9.26M
Li Yishan
Executive Chairman
124,779
$2.00M
Cui Jingrong Jean
President and CEO
124,779
$2.00M

No percentages here. BlossomHill Therapeutics, Inc. reports its share count only per share class, which the XBRL frames API does not carry.

Insider
Date
Role
Action
Shares
Price
Amount
Liptak Vincent Paul
10 Aug 2026
General Counsel
Buy
2,200
$16.00
$35.20K
Keyes Jason A
10 Aug 2026
Chief Financial Officer
Buy
700
$16.00
$11.20K
Chen Bihua
10 Aug 2026
Director
Buy indirect
312,500
$16.00
$5.00M
Schmid John P.
10 Aug 2026
Director
Buy
6,000
$16.00
$96.00K
ORBIMED ADVISORS LLC
10 Aug 2026
Director
Buy indirect
625,000
$16.00
$10.00M
GORDON CARL L
10 Aug 2026
Director
Buy indirect
625,000
$16.00
$10.00M
Liptak Vincent Paul
7 Aug 2026
General Counsel
Buy
2,500
$15.80
$39.50K

What was left out

Form 4 filings counted 11
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 11,759,095
History held since 10 Aug 2026